Get startedLog in
    Picture of HLS Therapeutics logo

    HLS — HLS Therapeutics News Story

    0.000.00%
    ca flag iconLast trade - 00:00
    HealthcareBalancedSmall CapNeutral
    All News

    Brief: Indivior Enters Into Exclusive License Agreement With HLS Therapeutics For Perseris

    Picture of HLS Therapeutics logoHLS Therapeutics
    09/05/2019 11:34
    May 9 (Reuters) - Indivior PLC  INDV.L :
    * LICENSING OF PERSERIS IN CANADA
    * ENTERS INTO EXCLUSIVE LICENSE AGREEMENT WITH HLS
THERAPEUTICS
FOR PERSERIS IN CANADA
    * UNDER TERMS OF AGREEMENT, INDIVIOR HAS GRANTED AN
EXCLUSIVE
LICENSE TO HLS TO FILE AND COMMERCIALIZE PERSERIS IN CANADA
    * ENTERED LICENSE AGREEMENT WITH HLS THERAPEUTICS FOR
EXCLUSIVE
COMMERCIALIZATION RIGHTS TO PERSERIS IN CANADA
    * WILL RECEIVE $1 MLN UPON SIGNING OF DEFINITIVE AGREEMENT
    * UPON COMMERCIALIZATION IN TERRITORY, CO ALSO ELIGIBLE TO
RECEIVE
ESCALATING DOUBLE-DIGIT ROYALTIES BASED ON ANNUAL NET SALES
    * WILL RECEIVE A NEAR-TERM PAYMENT OF $4 MLN CONTINGENT UPON
ACHIEVING CERTAIN REGULATORY AND PRE-COMMERCIAL MILESTONES

Source text for Eikon:  ID:nRSI5195Ya 
Further company coverage:  INDV.L 

 ((Reuters.Briefs@thomsonreuters.com;))

    Recent news on HLS Therapeutics

    See all news